Post Profile






Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

(European Society for Medical Oncology) The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers reported today at the ESMO 2016 Congress in Copenhagen.
read more

share

Related Posts


Phase III Study Showed Tarceva In Combination With Avastin As First-Line Maintenance Therapy Improved Progression-Free Survival In Lung Cancer

Health : Medical News Today

Genentech, Inc. (NYSE:DNA) announced that a Phase III study (ATLAS) of Tarceva® (erlotinib) in combination with Avastin® (bevacizumab) as maintenance therapy following initial treatment with Avastin plus chemotherapy in advanced non...

TTF Therapy In Combination With Chemotherapy Has The Potential To Increase Overall Survival For Patients With Advanced Non-Small Cell Lung Cancer

Health : Medical News Today

Novocure has reported that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously repo...

Precision Therapeutics' ChemoFx® Demonstrates Significant Role In Selection Of Chemotherapy Doublets In Non Small Cell Lung Cancer

Health : Medical News Today

Drs. Rodney Landreneau and Matthew Schuchert from the University of Pittsburgh presented a new non small cell lung cancer study at the 2011 Society of Surgical Oncology (SSO) conference in San Antonio, Texas. Dr. Landreneau is Direc...

Medical News Today: Study finds drug improves survival for patients with non-small cell lung cancer

Health : Medical News Today

A new phase 3 trial finds that overall survival is longer for patient with non-small cell lung cancer treated with the drug nivolumab compared with chemotherapy drug docetaxel.

Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

The first phase III study of PD-L1 inhibitor  atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.

Comments


Copyright © 2016 Regator, LLC